Department of Physiology, Brody School of Medicine, East Carolina University, Greenville, NC, USA; East Carolina Diabetes and Obesity Institute, Brody School of Medicine, East Carolina University, Greenville, NC, USA.
Pharmacol Ther. 2013 Dec;140(3):258-66. doi: 10.1016/j.pharmthera.2013.07.005. Epub 2013 Jul 15.
A major manifestation of coronary artery disease is cardiac ischemia/reperfusion injury, with the extent of injury directly relating to short- and long-term prognosis. Emerging evidence suggests that mitochondrial dysfunction is centrally involved in ischemia/reperfusion injury. In this review, we summarize the role of mitochondria in the etiology of ischemia/reperfusion injury. We attempt to highlight emerging areas for cardiac mitochondrial medicine and discuss recent advances regarding the molecular composition of inner membrane channels. We discuss interactions between lipids and proteins in the inner mitochondrial membrane, and the ever-evolving nature of this relationship during ischemia/reperfusion. Potentially novel treatments influencing the biophysical properties of inner membrane lipids (such as cardiolipin) are presented. Finally, we point to areas where future study is needed to expand and improve our understanding of mitochondrial pathophysiology during cardiac ischemia/reperfusion.
冠状动脉疾病的一个主要表现是心肌缺血/再灌注损伤，损伤的程度与短期和长期预后直接相关。新出现的证据表明，线粒体功能障碍在缺血/再灌注损伤中起着核心作用。在这篇综述中，我们总结了线粒体在缺血/再灌注损伤发病机制中的作用。我们试图强调心脏线粒体医学的新兴领域，并讨论关于内膜通道分子组成的最新进展。我们讨论了线粒体内膜中脂质和蛋白质之间的相互作用，以及在缺血/再灌注过程中这种关系的不断演变性质。提出了一些潜在的新治疗方法，这些方法影响内膜脂质（如心磷脂）的生物物理特性。最后，我们指出了需要进一步研究的领域，以扩大和提高我们对心肌缺血/再灌注期间线粒体病理生理学的理解。
